Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Interstitial lung disease)
63,782 results
  • Secondary pulmonary syphilis: Case report and review of literature. [Journal Article]
  • ADAnn Dermatol Venereol 2018 Feb 17
  • Kassem Youssef H, Blind A, … Michel C
  • CONCLUSIONS: Lung involvement in secondary syphilis is poorly known and rarely described. We found 27 cases of pulmonary syphilis reported in English and the main European languages since 1967. Mean age at diagnosis was 46 years with clear male predominance (89%). HIV co-infection was declared in 5 cases. Treponema pallidum was found in 6 patients using PCR on bronchoalveolar lavage (BAL) (3 patients) or on a lung biopsy (1 patient), immunohistochemistry (IHC) on BAL (1 patient) and Giemsa staining on a pleural fluid sample (1 patient). Chest X-rays may show unilateral or bilateral infiltrates or nodules with or without pleural effusion or hilar adenopathy. Sub-pleural involvement is frequent and penicillin is the treatment of choice.Pulmonary syphilitic involvement should be suspected where pulmonary symptoms or radiological changes occur in secondary syphilis. IHC, special staining or PCR on BAL, pleural fluid or lung tissue are useful for the identification of spirochetes.
  • Five-year experience using the Lung Allocation Score: the Munich Lung Transplant Group. [Journal Article]
  • EJEur J Cardiothorac Surg 2018 Feb 15
  • Schuba B, Scheklinski M, … Schramm R
  • CONCLUSIONS: Our centre-specific 5-year experience confirms previous findings demonstrating that the LAS is a well-established tool for the selection of lung transplant candidates, respecting urgency and prognostic transplant benefit in a disease-specific manner. However, the LAS did not shorten overall waiting times in transplanted patients. Further long-term and multicentre data with respect to differential transplant centre activities have to be gathered for further evaluation.
  • Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. [Journal Article]
  • AJAm J Clin Oncol 2018 Feb 21
  • Cohen RB, Delord JP, … Keam B
  • CONCLUSIONS: Pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, PD-L1-positive SGC.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
New Search Next